Images List Premium Download Classic

Psychiatric Disorders

Psychiatric Disorders-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Allosteric modulators of cb1 cannabinoid receptors
Northeastern University
July 13, 2017 - N°20170197918

The present invention relates to novel heterocyclic derivatives which are allosteric modulators of cannabinoid receptor 1 (cb1) and which are useful for the treatment or prevention of neurological and psychiatric disorders associated with endocannabinoid dysfunction and diseases in which the cb1 subtype of cannabinoid receptor is involved; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of ...
2-aryl-4-hydroxy-1,3-thiazole derivatives useful as trpm8-inhibitors in treatment of neuralgia, pain, copd and ...
Northeastern University
July 06, 2017 - N°20170190678

Said compounds are useful in the treatment of diseases associated with activity of trpm8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exacerbated respiratory disorders and urological disorders.
Method of treatment of schizophreniform disorder
Curemark, Llc
July 06, 2017 - N°20170189501

Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of ...
Psychiatric Disorders Patent Pack
Download + patent application PDFs
Psychiatric Disorders Patent Applications
Download + Psychiatric Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Psychiatric Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the m4 muscarinic acetylcholine receptor
Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center
June 29, 2017 - N°20170183342

The present invention is directed to 6,7-dihydro-5h-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the m4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which m4 muscarinic acetylcholine receptors are involved. The present invention is ...
Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Merck Patentgesellschaft
June 29, 2017 - N°20170182037

The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid ...
Heterocyclylalkyne derivatives and their use as modulators of mglur5 receptors
Merck Patentgesellschaft
June 29, 2017 - N°20170182011

Their use as allosteric modulators of mglur5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.
Psychiatric Disorders Patent Pack
Download + patent application PDFs
Psychiatric Disorders Patent Applications
Download + Psychiatric Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Psychiatric Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Exo-s-mecamylamine formulation and use in treatment
University Of South Florida
June 29, 2017 - N°20170181983

A pharmaceutical composition includes a therapeutically effective amount of exo-s-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-r-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0. 5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-s-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-r-mecamylamine, said ...
Botulinum toxin treatments of neurological and neuropsychiatric disorders
Allergan, Inc.
June 22, 2017 - N°20170173123

Methods for preventing or treating neuropsychiatric disorder and/or a neurological disorder including a neurological disorder mediated by the thalamus. Neuropsychiatric disorders and/or a neurological disorders, including a thalamically mediated disorder can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating a neurological disorder and/...
Methods for diagnosing and treating neuroimmune-based psychiatric disorders
The Regents Of The University Of California
June 15, 2017 - N°20170166968

The methods of the present invention are useful for determining whether an individual has or is at risk of developing a neuroimmune-based psychiatric disorder by detecting the expression level of one or more cytokine receptors in a biological sample. The methods of the present invention are also useful for the in vivo imaging of brain tissue by detecting one or ...
Mecp2e1 gene
Centre For Addiction And Metal Health
June 01, 2017 - N°20170152564

The invention is a novel mecp2e1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolythic feed-through, lead assembly and anchoring ...
Centre For Addiction And Metal Health
May 25, 2017 - N°20170143959

An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or ...
Mecp2e1 gene
Centre For Addiction And Mental Health
May 18, 2017 - N°20170137887

The invention is a novel mecp2e1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
6-amino-5,6,7,8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives
Hoffmann-la Roche Inc.
May 18, 2017 - N°20170137416

The present invention relates to compounds taar receptor antagonists of formula i wherein x, r, l, ar and r1 are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric disorders with compounds of formula i.
Psychiatric Disorders Patent Pack
Download + patent application PDFs
Psychiatric Disorders Patent Applications
Download + Psychiatric Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Psychiatric Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor ...
Vanderbilt University
May 11, 2017 - N°20170129889

In one aspect, the invention relates to substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m1 (machr m1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using ...
Trpm8 antagonists
Vanderbilt University
May 11, 2017 - N°20170129881

Said compounds are useful in the treatment of diseases associated with activity of trpm8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exacerbated respiratory disorders and urological disorders.
Orexin receptor antagonists
Vanderbilt University
May 04, 2017 - N°20170121320

Wherein w, x and y1, y2, y3 and y4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.
System and method for diagnosis and treatment of neuropsychiatric disorders
The Research Foundation For Mental Hygiene, Inc.
April 27, 2017 - N°20170114410

An assay for a gch1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the gch1 gene, alone or in conjunction with a measurement of low or altered ...
Novel tricyclic modulators of cannabinoid receptors
The University Of Montana
April 06, 2017 - N°20170096426

The compounds of the invention are modulators of cannabinoid receptors cb1 or cb2. The compounds can be used for the prevention or treatment of, e. G., pain, cancer, skin diseases, weight-associated disorders, chemical addictions, psychiatric disorders, neurodegenerative disorders, bone diseases, and inflammatory diseases. The compounds of the invention can further be used to study these diseases and disorders, as well ...
Peptides as oxytocin agonists
Hoffmann-la Roche Inc.
March 23, 2017 - N°20170081369

The present compounds compounds are oxytocin receptor agonists for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of prader-willi syndrome.
Peptides as oxytocin agonists
Hoffmann-la Roche Inc.
March 23, 2017 - N°20170081368

The present compounds are oxytocin receptor agonists for the treatment of autism, stress, including post-traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of prader-willi syndrome.
5-oxa-2-azabicyclo[2.2.2]octan-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives
Hoffmann-la Roche Inc.
March 09, 2017 - N°20170066775

The present invention relates to compounds of formula of formula i wherein x, ar, r1, m and n are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric disorders with compounds of formula i.
Loading